MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

Northern Tool + Equipment is bringing the high-octane excitement of Monster Jam® to the Little Rock community. On Thursday, February 20, customers will have the chance to experience the thrill-seeking ...

Utilizing new data from the Yardi® Matrix affordable housing database, the latest Yardi Matrix report on affordable housing explores the sector's current state of deliveries and ...

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, its small molecule telomere-targeting anticancer agent ...

EPA previously identified Acetic acid, [(γ-ω-perfluoro-C8-10-alkyl)thio] derivs., Bu esters for addition to the TRI list based on the NDAA’s provision to include specific PFAS upon the NDAA ...

A growing body of research suggests that exposure to PFAS, commonly called "forever chemicals," may increase a person's risk of developing cancer.

The US Environmental Protection Agency (EPA) has made a significant update to its Toxics Release Inventory (TRI) 1, automatically adding nine per- and polyfluoroalkyl substances (PFAS) to the list ...

This patent application pertains to macrocyclic peptides, generally represented by Formula I. These compounds exhibit selective binding to tumor necrosis factor receptor 1 (TNFR1) and hold the ...